Lozneanu L - Search Results

1

Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.

Rea K, Pinciroli P, Sensi M, Alciato F, Bisaro B, Lozneanu L, Raspagliesi F, Centritto F, Cabodi S, Defilippi P, Avanzi GC, Canevari S, Tomassetti A. Rea K, et al. Among authors: lozneanu l. Oncotarget. 2015 Oct 13;6(31):30859-75. doi: 10.18632/oncotarget.5087. Oncotarget. 2015. PMID: 26356564 Free PMC article.

2

Renal carcinogenesis--insights into signaling pathways.

Cojocaru E, Lozneanu L, Giuşcă SE, Căruntu ID, Danciu M. Cojocaru E, et al. Among authors: lozneanu l. Rom J Morphol Embryol. 2015;56(1):15-9. Rom J Morphol Embryol. 2015. PMID: 25826482 Free article. Review.

3

Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients.

Lozneanu L, Pinciroli P, Ciobanu DA, Carcangiu ML, Canevari S, Tomassetti A, Căruntu ID. Lozneanu L, et al. Anticancer Res. 2016 Aug;36(8):4155-63. Anticancer Res. 2016. PMID: 27466525

4

Involvement of AF1q/MLLT11 in the progression of ovarian cancer.

Tiberio P, Lozneanu L, Angeloni V, Cavadini E, Pinciroli P, Callari M, Carcangiu ML, Lorusso D, Raspagliesi F, Pala V, Daidone MG, Appierto V. Tiberio P, et al. Among authors: lozneanu l. Oncotarget. 2017 Apr 4;8(14):23246-23264. doi: 10.18632/oncotarget.15574. Oncotarget. 2017. PMID: 28423573 Free PMC article.

5

Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model.

Paris L, Podo F, Spadaro F, Abalsamo L, Pisanu ME, Ricci A, Cecchetti S, Altabella L, Buoncervello M, Lozneanu L, Bagnoli M, Ramoni C, Canevari S, Mezzanzanica D, Iorio E, Canese R. Paris L, et al. Among authors: lozneanu l. Oncotarget. 2017 Jul 5;8(33):55022-55038. doi: 10.18632/oncotarget.18992. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903399 Free PMC article.

6

Lesser-Known Molecules in Ovarian Carcinogenesis.

Lozneanu L, Cojocaru E, Giuşcă SE, Cărăuleanu A, Căruntu ID. Lozneanu L, et al. Biomed Res Int. 2015;2015:321740. doi: 10.1155/2015/321740. Epub 2015 Aug 3. Biomed Res Int. 2015. PMID: 26339605 Free PMC article. Review.

7

HER-2÷neu expression in different histological subtypes of papillary thyroid carcinoma.

Ciobanu Apostol D, Căruntu ID, Lozneanu L, Andriescu EC, Giuşcă SE. Ciobanu Apostol D, et al. Among authors: lozneanu l. Rom J Morphol Embryol. 2017;58(2):439-444. Rom J Morphol Embryol. 2017. PMID: 28730228 Free article.

8

Heterogeneous Periostin Expression in Different Histological Variants of Papillary Thyroid Carcinoma.

Giusca SE, Amalinei C, Lozneanu L, Ciobanu Apostol D, Andriescu EC, Scripcariu A, Balan R, Avadanei ER, Căruntu ID. Giusca SE, et al. Among authors: lozneanu l. Biomed Res Int. 2017;2017:8701386. doi: 10.1155/2017/8701386. Epub 2017 Dec 25. Biomed Res Int. 2017. PMID: 29435461 Free PMC article.

9

Insights into molecular pathways of endometriosis and endometriosis-related ovarian carcinoma.

Păvăleanu I, Lozneanu L, Balan RA, Giuşcă SE, Avădănei ER, Căruntu ID, Amălinei C. Păvăleanu I, et al. Among authors: lozneanu l. Rom J Morphol Embryol. 2020 Jul-Sep;61(3):739-749. doi: 10.47162/RJME.61.3.12. Rom J Morphol Embryol. 2020. PMID: 33817715 Free PMC article.

10

High variability in MMP2/TIMP2 and MMP9/TIMP1 expression in secondary liver tumors.

Avădanei R, Căruntu ID, Amălinei C, Lozneanu L, Balan R, Grigoraş A, Ciobanu Apostol D, Giuşcă SE. Avădanei R, et al. Among authors: lozneanu l. Rom J Morphol Embryol. 2013;54(3):479-85. Rom J Morphol Embryol. 2013. PMID: 24068394 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

56 results

Search Page